Endocrine factors in the outcome of systemic adjuvant therapy of early breast cancer

Ann N Y Acad Sci. 1993 Nov 30:698:330-8. doi: 10.1111/j.1749-6632.1993.tb17223.x.
No abstract available

Publication types

  • Clinical Trial
  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Breast Neoplasms / drug therapy
  • Breast Neoplasms / mortality
  • Breast Neoplasms / pathology
  • Breast Neoplasms / therapy*
  • Cyclophosphamide / administration & dosage
  • Female
  • Fluorouracil / administration & dosage
  • Humans
  • Melphalan / administration & dosage
  • Methotrexate / administration & dosage
  • Middle Aged
  • Ovariectomy*
  • Postmenopause
  • Premenopause
  • Receptors, Estrogen / analysis
  • Receptors, Progesterone / analysis
  • Retrospective Studies
  • Survival Rate
  • Tamoxifen / therapeutic use*
  • Treatment Outcome

Substances

  • Receptors, Estrogen
  • Receptors, Progesterone
  • Tamoxifen
  • Cyclophosphamide
  • Melphalan
  • Fluorouracil
  • Methotrexate

Supplementary concepts

  • CMF regimen